Despite a similar hypouricemic effect of the XO inhibitors on blood UA level, febuxostat, but not allopurinol, significantly decreased hepatic XO activity and UA levels in the NASH model mice. Here, XDH is linked to metabolic dysfunction-associated steatohepatitis.